PriceTargets.com logo

Eisai - ESALY Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$61.51 As of 01/30/2023 10:04 PM ET
▼ -1.325 (-2.11%)

This chart shows the closing price for ESALY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Eisai Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ESALY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ESALY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Eisai in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $61.51.

This chart shows the closing price for ESALY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 3 polled investment analysts is to moderate buy stock in Eisai. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/25/2023CitigroupUpgradeNeutral ➝ Buy
5/23/2023Sanford C. BernsteinInitiated CoverageOutperform
9/28/2022Morgan StanleyUpgradeUnderweight ➝ Equal Weight
1/13/2022CitigroupDowngradeBuy ➝ Neutral
6/25/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight
6/17/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
11/5/2020Jefferies Financial GroupUpgradeHold ➝ Buy
9/8/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
9/24/2019Jefferies Financial GroupInitiated CoverageBuy
9/17/2019Daiwa Capital MarketsDowngradeNeutral ➝ Sell
8/5/2019CitigroupUpgradeSell ➝ Neutral
3/25/2019UBS GroupReiterated RatingNeutral ➝ Sell
3/22/2019Nomura SecuritiesReiterated RatingBuy ➝ Reduce
3/22/2019CitigroupDowngradeNeutral ➝ Sell
(Data available from 9/27/2018 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/1/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/31/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/30/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Eisai logo
Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.
Read More

Today's Range

Now: $61.51
Low: $61.00
High: $63.29

50 Day Range

MA: $61.51
Low: $61.51
High: $61.51

52 Week Range

Now: $61.51
Low: $36.88
High: $73.90

Volume

331,800 shs

Average Volume

60,916 shs

Market Capitalization

$17.64 billion

P/E Ratio

70.70

Dividend Yield

1.43%

Beta

0.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Eisai?

The following equities research analysts have issued stock ratings on Eisai in the last year: Citigroup Inc., Morgan Stanley, and Sanford C. Bernstein.
View the latest analyst ratings for ESALY.

What is the current price target for Eisai?

0 Wall Street analysts have set twelve-month price targets for Eisai in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Eisai in the next year.
View the latest price targets for ESALY.

What is the current consensus analyst rating for Eisai?

Eisai currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ESALY.

What other companies compete with Eisai?

Other companies that are similar to Eisai include Shionogi & Co., Ltd., H. Lundbeck A/S, bioMérieux, Eurofins Scientific and Sysmex. Learn More about companies similar to Eisai.

How do I contact Eisai's investor relations team?

Eisai's physical mailing address is 4-6-10 Koishikawa Bunkyo-ku, Tokyo M0, 112-8088. The company's listed phone number is (133) 817-3700. The official website for Eisai is www.eisai.co.jp. Learn More about contacing Eisai investor relations.